Investors
Agios is a biopharmaceutical company passionately committed to applying our scientific leadership in the field of cellular metabolism to transform the lives of patients with cancer and rare genetic diseases.
Stock is 
Press Release
 View printer-friendly version << Back

Agios Announces Revised Starting Time of 8:00am ET for Investor Day and First Quarter 2018 Financial Results Webcast on Friday, May 4, 2018

CAMBRIDGE, Mass., April 27, 2018 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that the company will webcast presentations from its Investor Day, including first quarter financial results, on Friday, May 4, 2018 at 8:00 a.m. ET in New York.

Presentations will be given by members of Agios' leadership team and external speakers including:

  • David Schenkein, M.D., Chief Executive Officer
  • Scott Biller, Ph.D., Chief Scientific Officer
  • Chris Bowden, M.D., Chief Medical Officer
  • Andrew Hirsch, Chief Financial Officer and Head of Corporate Development
  • Steve Hoerter, Chief Commercial Officer
  • Darrin Miles, Vice President, IDH Program Management
  • Susan Pandya, M.D., Senior Medical Director, Clinical Development
  • Kevin Marks, Ph.D., Senior Director, Head of Cancer Biology
  • Maeve Lowery, M.B., B.Ch., B.A.O, Trinity College Dublin

A live webcast of the presentations can be accessed under "Events & Presentations" in the Investors section of the company's website at www.agios.com. The presentations are scheduled to begin at 8:00 a.m. ET and conclude at 12:00 p.m. ET. A replay of the webcast will be archived on the Agios website for at least two weeks following the presentation.

About Agios
Agios is focused on discovering and developing novel investigational medicines to treat cancer and rare genetic diseases through scientific leadership in the field of cellular metabolism. In addition to an active research and discovery pipeline across both therapeutic areas, Agios has an approved oncology precision medicine and multiple first-in-class investigational therapies in clinical and/or preclinical development. All Agios programs focus on genetically identified patient populations, leveraging our knowledge of metabolism, biology and genomics. For more information, please visit the company's website at www.agios.com.

Investors:
Renee Leck, 617-649-8299
Senior Manager, Investor Relations
Renee.Leck@agios.com

Media:
Holly Manning, 617-844-6630
Associate Director, Corporate Communications
Holly.Manning@agios.com

Primary Logo

Source: Agios Pharmaceuticals, Inc.